Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ABBV 166

Next Previous
Drug Profile

ABBV 166

Alternative Names: ABBV-066 + ABT-981; ABBV-166; Risankizumab + lutikizumab

Latest Information Update: 31 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AbbVie
  • Class Anti-inflammatories; Antiasthmatics; Antipsoriatics; Antirheumatics; Bispecific antibodies; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 1 alpha inhibitors; Interleukin 1 beta inhibitors; Interleukin-23 subunit p19 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Crohn's disease; Psoriatic arthritis

Most Recent Events

  • 11 Apr 2025 Phase-II clinical trials in Psoriatic arthritis (Combination therapy, Treatment-resistant) in Poland, France, Hungary, Czech Republic, USA, Canada (SC) (NCT06865105)
  • 04 Sep 2024 Phase-II clinical trials in Crohn's disease (Combination therapy, Treatment-resistant) in United Kingdom, Turkey, Taiwan, Switzerland, Spain, South Korea, Slovenia, Slovakia, Singapore, Serbia, Romania, Portugal, Poland, Norway, Netherlands, Lithuania, Latvia, Italy, Ireland, Israel, Hungary, Germany, France, Estonia, Czech Republic, Croatia, Canada, Bulgaria, Belgium, Austria, USA (SC) (NCT06548542)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top